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The bromodomain and extraterminal (BET) family of proteins comprises four members-BRD2, BRD3, BRD4 and the testisspecific isoform BRDT-that largely function as transcriptional coactivators [1] [2] [3] and play critical roles in various cellular processes, including the cell cycle, apoptosis, migration and invasion 4, 5 . BET proteins enhance the oncogenic functions of major cancer drivers by elevating the expression of these drivers, such as c-Myc in leukemia 6, 7 , or by promoting the transcriptional activities of oncogenic factors, such as AR and ERG in prostate cancer 8 . Pathologically, BET proteins are frequently overexpressed and are clinically linked to various types of human cancer 5, 9, 10 ; they are therefore being pursued as attractive therapeutic targets for selective inhibition in patients with cancer. To this end, a number of bromodomain inhibitors, including JQ1 and I-BET, have been developed 11, 12 and have shown promising outcomes in early clinical trials. Although resistance to BET inhibitors has been documented in preclinical models [13] [14] [15] , the molecular mechanisms underlying acquired resistance are largely unknown. Here we report that cullin-3 SPOP earmarks BET proteins, including BRD2, BRD3 and BRD4, for ubiquitination-mediated degradation. Pathologically, prostate cancer-associated SPOP mutants fail to interact with and promote the degradation of BET proteins, leading to their elevated abundance in SPOP-mutant prostate cancer. As a result, prostate cancer cell lines and organoids derived from individuals harboring SPOP mutations are more resistant to BET-inhibitor-induced cell growth arrest and apoptosis. Therefore, our results elucidate the tumorsuppressor role of SPOP in prostate cancer in which it acts as a negative regulator of BET protein stability and also provide a molecular mechanism for resistance to BET inhibitors in individuals with prostate cancer bearing SPOP mutations.
Given that resistance to targeted therapies is frequently associated with accumulation of the therapeutic target [16] [17] [18] , it is crucial to understand how BET protein stability is regulated and whether deregulation of BET protein abundance contributes to cellular resistance to BET inhibitors. To this end, we observed that, in 22Rv1 prostate cancer cells, treatment with the proteasome inhibitor MG132 and the cullin-RING ubiquitin ligase inhibitor MLN4924 led to a marked increase in endogenous BRD4 abundance, indicating the involvement of cullinbased ligase(s) in the regulation of BRD4 protein stability (Fig. 1a) . In support of this notion, we found that BRD4 primarily interacted with cullin-3 (CUL3) and, to a much lesser extent, cullin-1 (CUL1), but not with other members of the cullin family (Fig. 1b) . Ectopic expression of CUL3 decreased the abundance of BRD4 in a dose-dependent manner (Supplementary Fig. 1a ). On the other hand, depletion of endogenous CUL3, but not CUL1, CUL4A or CUL4B, led to a marked elevation of endogenous BRD2, BRD3 and BRD4 protein levels ( Fig. 1c and Supplementary Fig. 1b Fig. 1d,e) . These data suggest that CUL3-based ligase(s) might be responsible for governing BET protein stability. Previous studies have demonstrated that CUL3 recruits substrates downstream of the ubiquitin ligase through interaction with BTB-domain-containing proteins that act as substrate-specific adaptors, including Kelch-like protein 20 (KLHL20), Kelch-like ECHassociated protein 1 (KEAP1) and speckle-type POZ protein (SPOP) 19 . Interestingly, we found that only SPOP of the CUL3-based BTBdomain-containing adaptor proteins we examined specifically interacted with BET proteins (Fig. 1d and Supplementary Fig. 1f-i) . Notably, SPOP, but not KEAP1 or hCOP1, a cullin-4 (CUL4)-based E3 ligase substrate adaptor protein 20 , promoted BET protein degradation in a dose-dependent manner ( Fig. 1e and Supplementary  Fig. 1j-l) . More notably, SPOP-mediated degradation of BRD4 could be efficiently blocked by MG132 (Supplementary Fig. 1m ), indicating that SPOP regulates BRD4 protein abundance through the ubiquitin-proteasome pathway. In keeping with these findings, depletion of endogenous SPOP by short hairpin RNA (shRNA)-mediated knockdown or CRISPR-mediated knockout in multiple prostate cancer cell lines and mouse embryonic fibroblasts (MEFs) led to a marked increase in the abundance of BET proteins as well as other identified SPOP substrates, including DEK, androgen receptor (AR) and ERG ( Fig. 1f-h and Supplementary Fig. 1n,o) . Moreover, we found that SPOP, but not the other CUL3-based adaptor proteins we examined or hCOP1, specifically promoted BET protein ubiquitination in cells ( Fig. 1i and Supplementary  Fig. 1p,q) . Notably, BRD4 mRNA levels were minimally changed in SPOP-depleted cells (Supplementary Fig. 1r ), whereas the half-life of BRD4 was markedly extended (Fig. 1j,k and Supplementary Fig. 1s,t) . These results collectively suggest that members of the BET family of proteins, including BRD2, BRD3 and BRD4, are potential substrates of the CUL3 SPOP E3 ubiquitin ligase.
Next, we sought to understand what role the biological effects of SPOP have in governing BRD4 stability. BRD4 has been previously shown to play a critical role in cell proliferation, migration and invasion by directly associating with positive transcription elongation factor b (P-TEFb) 21, 22 or by interacting with DNA-sequence-specific transcription factors, including p53, c-Myc, AR and ERG 8, 23 . In accordance with BRD4 having a critical role as a transcriptional coactivator for AR and ERG 8, 23 , we first confirmed that BET proteins bound both endogenous and ectopically expressed AR and ERG in 22Rv1 and HEK293 cells (Supplementary Fig. 2a-c) . Moreover, depletion of SPOP significantly upregulated the mRNA levels of AR and ERG target genes, largely in a BRD4-dependent manner, in prostate cancer cells (Supplementary Fig. 2d-g ). In keeping with this finding, the mRNA levels of AR and ERG target genes were significantly decreased in BRD4-knockout or JQ1-treated C4-2 prostate cancer cells (Supplementary Fig. 2h-l) . Notably, stable expression of AR or ERG in BRD4-knockout cells failed to restore the expression of downstream target genes ( Supplementary Fig. 2m-p) , indicating that BRD4 plays a critical role as a coactivator in controlling AR and ERG transcriptional activity. We observed that, in comparison with the control (scrambled shRNA), depletion of BRD4 led to significant inhibition of cell proliferation (Fig. 1l) , colony formation (Fig. 1m) , anchorage-independent growth (Fig. 1n) and migration ( Fig. 1o-q) . In contrast, depletion of endogenous SPOP led to a marked elevation of BRD4 protein abundance ( Fig. 1o and Supplementary  Fig. 2g ) and a BRD4-dependent increase in cell proliferation ( Fig. 1l and Supplementary Fig. 2q,r) , colony formation (Fig. 1m) , anchorage-independent growth (Fig. 1n) and migration ( Fig. 1o-q) relative to the control. Moreover, cells with simultaneous depletion of endogenous BRD4 together with AR or ERG displayed a similar proliferation rate and migration ability as cells with individual depletion of either AR or ERG (Fig. 1o-q and Supplementary Fig. 2s-v) . Altogether, these data suggest that SPOP suppresses prostate cancer progression largely by targeting BRD4 for ubiquitination and subsequent destruction, resulting in attenuation of BRD4-dependent AR and ERG signaling in prostate cancer (Supplementary Fig. 2w ).
SPOP is a member of the MATH-BTB protein family, containing an N-terminal meprin and TRAF homology (MATH) domain and a C-terminal BTB domain 24 . The MATH domain is responsible for substrate recognition and interaction while the BTB domain binds CUL3, forming the functional E3 ubiquitin ligase complex. Recent genomewide sequencing studies have revealed that SPOP is the most frequently mutated gene (in up to 10% of cases) in prostate cancers 25, 26 . Interestingly, all SPOP somatic mutations identified in prostate cancers, including those encoding p.Y87C, p.F102C, p.W131G and p.F133V substitutions, affect the MATH domain (Fig. 2a) and have a dominant-negative effect on substrate binding and degradation 27 . In keeping with previous reports 24, 28 , we found that deletion of the MATH domain abolished SPOP interaction with BRD4 (Fig. 2b) , and both the MATH and BTB domains were required for SPOP-mediated BRD4 ubiquitination and degradation ( Fig. 2c and Supplementary  Fig. 3a) . Next, we sought to explore whether prostate cancerassociated SPOP mutations affect BRD4 stability. Notably, all of the mutants we examined failed to interact with BRD2, BRD3 and BRD4 in HEK293 and prostate cancer cells ( Fig. 2d and Supplementary  Fig. 3b-d ) and were thereby deficient in promoting the degradation of BET proteins ( Fig. 2e and Supplementary Fig. 3e-h) . Moreover, ectopic expression of wild-type SPOP (WT-SPOP), but not the SPOP mutants, substantially shortened the half-life of BRD4 ( Fig. 2f and Supplementary Fig. 3i ) relative to wild type and promoted ubiquitination of BET proteins in cells ( Fig. 2g and Supplementary Fig. 3j,k) .
In keeping with these findings, prostate tissue derived from mice with induced expression of human F133V-SPOP in the prostate also exhibited increased abundance of BRD2, BRD3 and BRD4 (Supplementary Fig. 3l ). In accordance, stable expression of SPOP mutants in prostate cancer cells increased mRNA levels of ERG target genes in comparison to ectopic expression of WT-SPOP (Supplementary Fig. 3m ). Human C4-2 prostate cells expressing prostate cancer-derived SPOP mutants displayed enhanced colonyformation ability in monolayer culture and increased growth on a 3D extracellular matrix when compared with cells expressing WT-SPOP ( Fig. 2h and Supplementary Fig. 4a ), processes that could be largely abolished by depleting endogenous BRD4 (Fig. 2i and Supplementary  Fig. 4b ). In line with this finding, depletion of BRD4 by CRISPRmediated knockout or shRNA-mediated knockdown in C4-2 cells expressing SPOP mutants significantly retarded the growth of tumor xenografts in mouse models (Fig. 2j-l and Supplementary Fig. 4c-k) . Taken together, these results suggest a physiological role for BRD4 in promoting cell proliferation and in vivo prostate tumorigenesis downstream of prostate cancer-specific SPOP mutations.
To further evaluate the clinical relevance of SPOP-mediated BRD4 degradation, we performed BRD4 immunohistochemistry (IHC) on 66 specimens with WT SPOP and 12 specimens with SPOP mutations from individuals with prostate cancer 28 and observed an inverse correlation between SPOP mutation status and BRD4 levels (Fig. 2m,n) . Moreover, BRD4 expression gradually increased with advancing prostate cancer stage 29 , from lower levels in benign prostatic hyperplasia (BPH) to higher levels in castration-resistant prostate cancer (CRPC), In all plots, data are shown as mean ± s.d. for three independent experiments. In immunoblots, vinculin was used as a loading control. A t-test was used for statistical calculations in l-n and q. *P < 0.05, **P < 0.01. A t-test was used for statistical calculations in h, i and l, and a chi-squared test was used in n. *P < 0.05, **P < 0.01. and higher BRD4 expression was significantly associated with shorter overall, disease-specific and prostate-specific antigen (PSA) recurrence-free survival after radical prostatectomy in primary prostate cancer (Supplementary Fig. 5a-c) . Furthermore, using two-class paired significance analysis of microarrays in normal-tumor pairs to compute transcriptome-wide differential test statistics (d-statistics), we found a strong correlation (ρ = 0.83, P < 2.2 × 10 −16 ) between the two sets of d-statistics, suggesting that mRNA-level changes associated with SPOP mutations largely overlap with the changes associated with high expression of BRD4 (Supplementary Fig. 5d ). Collectively, these data suggest that SPOP mutations result in elevated BRD4 protein abundance, which is associated with prostate cancer progression.
To gain further insights into how SPOP governs BRD4 stability, we next examined the specific region(s) of BRD4 that interact with SPOP (Fig. 3a) . Interestingly, SPOP specifically interacted with and promoted the degradation of the bromodomain region (amino acids 1-470) but did not interact with other regions of BRD4 (Fig. 3b,c) . A previous study reported that well-characterized substrates of SPOP contain a Φ-Π-S-S/T-S/T consensus motif (where Φ is a nonpolar residue and Π is a polar residue) 24 . Upon examination of amino acids 1-470, we identified one evolutionarily conserved putative SPOPbinding motif, or 'degron' , in all of the BET family members (Fig. 3d) . Strikingly, deletion of the identified degron (∆D) led to abolishment of the interaction between BET proteins and SPOP in cells and in vitro (Fig. 3e and Supplementary Fig. 6a-e) . Moreover, the degrondeleted BET protein mutants were resistant to SPOP-mediated degradation ( Fig. 3f and Supplementary Fig. 6f-h) . As a result, the half-life of the ∆D-BRD4 mutant was markedly extended in comparison with that of WT-BRD4 (Fig. 3g,h and Supplementary Fig. 6i,j) . In accordance with these findings, when compared with WT-BRD4, the ∆D-BRD4 mutant was largely deficient in undergoing SPOPmediated ubiquitination in cells and in vitro (Fig. 3i,j and  Supplementary Fig. 6k ). These results together indicate that the identified degron is the major motif that is responsible for SPOPdependent regulation of BRD4 stability.
Interestingly, analysis of the Catalogue of Somatic Mutations in Cancer (COSMIC) cancer database (see URLs) identified a somatic mutation encoding p.T295P in individuals with cancer mapping to the degron motif of BRD4, which may disrupt the canonical SPOPbinding motif (Supplementary Fig. 6l) . Indeed, we observed that the T295P-BRD4 mutant failed to interact with SPOP in HEK293 cells (Supplementary Fig. 6m ). As such, in comparison to WT-BRD4, the T295P-BRD4 mutant was resistant to SPOP-mediated ubiquitination and subsequent degradation (Supplementary Fig. 6n-q) . These results indicate that the p.T295P substitution may stabilize BRD4 and enhance its oncogenic role in tumorigenesis, in part by allowing it to evade SPOP-mediated degradation.
Next, we sought to explore the physiological roles of degronmediated BRD4 degradation by SPOP in the prostate cancer setting. In this analysis, we found that ectopic expression of WT-BRD4 and, to a greater extent, the nondegradable ∆D-BRD4 mutant promoted cell proliferation and migration (Fig. 3l-n) , supporting a possible oncogenic role for BRD4. More notably, coexpression of SPOP with exogenous BRD4 suppressed WT-BRD4-but not ∆D-BRD4-mediated cell proliferation and migration (Fig. 3l-n) , largely owing to the ability of the ectopically expressed SPOP to efficiently promote the degradation of WT-BRD4 but not the ∆D-BRD4 mutant (Fig. 3k) , for which interaction with SPOP was impaired (Fig. 3e) .
Notably, several BET inhibitors have been developed that mechanically disrupt the interaction of bromodomain proteins such as BRD4 with acetylated histones, leading to inhibition of transcription, cell growth and tumorigenesis 11, 12 . Early clinical trials showed that BET inhibitors display promising therapeutic outcomes in patients 4 . However, more recent studies have identified mechanisms of resistance to BET inhibitors in leukemia and triple-negative breast cancer involving elevation of Wnt-β-catenin signaling and hyperphosphorylation of BRD4, respectively [13] [14] [15] . Therefore, it is crucial to investigate whether deficiencies in BRD4 degradation resulting from SPOP mutation may confer resistance to BET inhibitors in prostate cancer cells. Interestingly, we observed that depletion of BRD4 by shRNA-mediated knockdown or CRISPR-mediated knockout could sensitize prostate cancer cells to the BET inhibitors JQ1 and I-BET (Fig. 4a,b and Supplementary Fig. 7a-e) . In contrast, depletion of endogenous SPOP by shRNA or CRISPR-mediated knockout, which stabilized BRD4 (Supplementary Fig. 7a) , reduced sensitivity to JQ1 and I-BET (Fig. 4a,b and Supplementary Fig. 7c-f) and inhibited JQ1-induced suppression of cellular migration ( Supplementary  Fig. 7g,h) . Furthermore, additional depletion of BRD4 re-sensitized SPOP-depleted cells to JQ1 (Fig. 4b) , suggesting that SPOP-deficient cells acquired resistance to BET inhibitors largely through elevation of BRD4 protein abundance.
In keeping with the notion that BET proteins are the primary targets of JQ1 (ref. 11), cells simultaneously depleted of endogenous BRD2, BRD3 and BRD4 displayed a decreased proliferation rate and were less responsive to JQ1 treatment in comparison to control cells without knockdown ( Supplementary Fig. 7i-l) . In contrast, stable expression of other SPOP substrates, such as AR and ERG, in BRD4-knockout cells failed to restore JQ1 resistance (Supplementary Fig. 7m-o) , indicating that all the BET proteins-BRD2, BRD3 and BRD4-are likely JQ1 drug targets and that their levels functionally contribute to JQ1 resistance in prostate cancer. In line with this notion, stable expression of WT-SPOP, but not the BRD4-interaction-deficient SPOP mutants, in C4-2 or LNCaP prostate cancer cells conferred sensitivity to JQ1 and I-BET ( Fig. 4c and Supplementary Fig. 8a-g ), with the difference in outcome presumably due to the distinct behavior of the SPOP proteins in dictating abundance of endogenous BET proteins in prostate cancer cells (Fig. 2e and Supplementary Fig. 3h) . Moreover, when compared to tumor xenografts with WT-SPOP, those with W131G-SPOP were resistant to JQ1 treatment in a mouse model (Fig. 4d-f and Supplementary Fig. 8h-j) . Notably, depletion of BRD4, but not other SPOP substrates such as DEK, TRIM24 or ERG, could largely resensitize SPOP-deficient cells to JQ1 in C4-2 and 22Rv1 prostate cancer cells (Fig. 4g,h and Supplementary  Fig. 8k-x) .
Furthermore, in keeping with the notion that BRD4 protein levels dictate cellular sensitivity to BET inhibitors, we found that ectopic expression of WT-BRD4 or the nondegradable ∆D-BRD4 mutant at comparable levels allowed cells to acquire resistance to JQ1 treatment ( Supplementary Fig. 9a,b) . More notably, coexpression of WT-SPOP with these BRD4 proteins could suppress WT-BRD4-but not ∆D-BRD4-mediated JQ1 resistance (Supplementary Fig. 9c-e) . In accordance with this, BRD4-knockout C4-2 prostate cancer cells reconstituted with the nondegradable T295P-BRD4 mutant were relatively more stable than those reconstituted with WT-BRD4 (Supplementary Fig. 9f,g ), in part owing to the inability of the mutant to interact with SPOP (Supplementary Fig. 6m) . Depletion of SPOP in these cell lines elevated the protein abundance of stably expressed WT-BRD4 but not that of T295P-BRD4 (Supplementary Fig. 9h ). In comparison with cells reconstituted with T295P-BRD4, cells overexpressing WT-BRD4 were relatively more sensitive to JQ1, largely in an l e t t e r s In all plots, data are shown as mean ± s.d. for three independent experiments. In immunoblots, vinculin was used as a loading control. A t-test was used for statistical calculations in l and n. *P < 0.05, **P < 0.01; ns, not significant. Fig. 9i ). In keeping with these outcomes, depletion of SPOP inhibited JQ1-induced cellular apoptosis predominantly in a BRD4-dependent manner ( Fig. 4i and Supplementary Fig. 9j-l) . On the other hand, ectopic expression of WT-SPOP, but not the prostate cancer-derived W131G-SPOP mutant, promoted cellular apoptosis upon JQ1 treatment, in part through its destabilization of BRD4 ( Fig. 4j and Supplementary Fig. 3h ). Taken together, these data suggest that elevated protein levels of BRD4 might contribute to the observed resistance to BET inhibitors in prostate cancer cells.
To further investigate whether SPOP-deficiency-induced accumulation of BRD4 contributes to JQ1 resistance in clinical models, we identified an organoid derived from an individual with prostate cancer harboring a mutation in SPOP encoding p.W131R. Similar to other known prostate cancer-derived SPOP mutants, the W131R-SPOP mutant also failed to promote ubiquitination and subsequent degradation of BET proteins, largely owing to impaired binding of the mutant SPOP to BET proteins (Supplementary Fig. 9m-q) . As a result, prostate cancer cells stably expressing the W131R-SPOP mutant were resistant to JQ1 treatment ( Supplementary Fig. 9r-t) . In line with the results from the cell culture model, when compared with organoids expressing WT-SPOP, the organoid expressing W131R-SPOP exhibited increased protein abundance of many SPOP substrates, including the BET proteins, SRC3 and TRIM24 (Fig. 4k) and it subsequently became more resistant to JQ1 treatment in both 2D and 3D culture conditions (Fig. 4l,m) . More notably, depletion of BRD4 resensitized the organoid expressing W131R-SPOP to JQ1 treatment (Fig. 4n,o) , providing evidence that BRD4 protein abundance, but not genetic background differences among WT-SPOP-and mutant-SPOP-expressing organoids, accounts for the observed JQ1 resistance in SPOP-mutant cells.
Having demonstrated a critical role for the SPOP-BRD4 signaling axis in mediating BET inhibitor resistance, we next explored how to target BRD4 in prostate cancer cells harboring mutant SPOP to achieve better clinical outcomes. Recently, ligand-induced target protein degradation, such as phthalimides-based cereblon-mediated degradation of transcription factors Ikaros family zinc-finger protein 1 (IKZF1) and IKZF3 (refs. 30,31) , has emerged as a promising therapeutic strategy for cancer. To this end, dBET1, which is a hybrid compound of JQ1 and thalidomide, could specifically promote CUL4 cereblon -dependent degradation of BET proteins 32 . Notably, we found that, in comparison to parental C4-2 cells, SPOP-knockout cells were relatively resistant to dBET1, similar to their response to other BET inhibitors; however, BRD4-knockout cells were more sensitive to dBET1 than the parental cells (Supplementary Fig. 10a) , largely owing to the fact that, in SPOP-knockout cells with elevated BRD4 protein abundance, dBET1 in low concentrations cannot efficiently promote the timely degradation of BRD4 to trigger cellular apoptosis (Supplementary Fig. 10b) . Notably, we confirmed that the expression of cereblon was comparable in SPOP-knockout cells and parental cells (Supplementary Fig. 10c) . Moreover, dBET1 could efficiently promote BRD4 degradation in HEK293FT and MM.1S cells with wild-type levels of CRBN (encoding cereblon) but not in those with CRBN knockout (Supplementary Fig. 10d,e) . These results confirm that cereblon is the major E3 ligase mediating dBET1-induced degradation of BRD4 protein. To further examine whether BRD4 protein abundance also dictates cellular sensitivity to dBET1, we treated the SPOP-knockout cells with increasing doses of dBET1. We found that dBET1 sensitivity gradually increased and that dBET-1 could promote BRD4 degradation at high doses (Supplementary Fig. 10f) . Moreover, in SPOP-knockout cells, dBET1 could promote BRD4 degradation when BRD4 abundance was decreased to levels comparable to those in parental cells (Supplementary Fig. 10g) .
Taken together, the results of our study uncover a critical tumorsuppressive role of SPOP in prostate cancer whereby it earmarks the BRD4 oncoprotein for timely destruction. Furthermore, we show that impairment of this signaling axis by mutations either at the level of the E3 ligase (SPOP) or the substrate (BRD4) can prevent SPOP-mediated destruction of BRD4 by disrupting SPOP-BRD4 interaction, leading to stabilization and cooperation of BRD4 with various oncogenic transcription factors, including AR and ERG, to facilitate prostate tumorigenesis (Supplementary Fig. 2w) . Notably, somatic mutations in SPOP are mutually exclusive with the ERG gene fusion 25 , which is the most frequent genetic alteration in prostate cancer, occurring in over 50% of cases and leading to elevation of both mRNA and protein levels of ERG and its downstream targets in a dominant fashion to promote cellular migration and invasion 33, 34 . Our previous study demonstrated that SPOP deficiency caused by either SPOP mutation or depletion of endogenous SPOP leads to a moderate increase of ERG protein levels, promoting cellular migration 28 . Our current study suggests that, in SPOP-deficient prostate cancer cells, elevated levels of the BRD4 transcriptional coactivator might synergize with a moderate increase in ERG abundance to favor cell migration and subsequent tumorigenesis. Moreover, our results also provide a possible molecular mechanism for BET inhibitor resistance in prostate cancer cells harboring SPOP mutations, which largely involves stabilization of BET oncoproteins (Fig. 4p) . We are aware that some prostate cancer samples with WT SPOP also exhibit high protein levels of BRD4 (Fig. 2n) , indicating that other mechanisms, such as transcriptional regulation or genetic amplification, could also lead to BRD4 accumulation independently of mutations in SPOP, and these mechanisms warrant future in-depth study. Given the critical oncogenic role of BRD4 and the high frequency of SPOP mutations in prostate cancer, our findings provide a molecular rationale for the clinical investigation of new strategies to combat prostate cancer based on SPOP genetic status.
URLs. COSMIC database, http://cancer.sanger.ac.uk/cosmic/; TCGA, http://cancergenome.nih.gov/; cBioPortal, http://www.cbioportal.org/.
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